J&J’s Bedaquiline Advisory Cmte. Could Test Strength Of Phase II Argument For Tuberulosis Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Anti-Infective Drugs Advisory Committee will review J&J’s product, a diarylquinolone, for the treatment of multi-drug resistant pulmonary tuberculosis on Nov. 28.
You may also be interested in...
Emerging Markets Focused J&J’s Sirturo Approval Tied To Expansive Post-Marketing Study Program
The first drug approved for multi-drug resistant tuberculosis, Sirturo obtained accelerated approval based on data from two Phase II studies, but has a troubling safety database, including 10 deaths in the treatment arm of its Phase II program.
J&J’s Sirturo Approval Tied To Expansive Post-Marketing Study Program
The first drug approved for multi-drug resistant tuberculosis, Sirturo obtained accelerated approval based on data from two Phase II studies, but has a troubling safety database, including 10 deaths in the treatment arm of its Phase II program.
Janssen’s Sirturo: TB Milestone Awaits After Advisory Committee Hurdle
Important safety questions remain for what could be the first new tuberculosis drug in 40 years, and there was a lack of efficacy in the key subgroup of black patients.